Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 3701–3750 of 76264
the Board of Directors (the “Board”) of Navitas Semiconductor Corporation (the “Company”) appointed Davin D. Lee to serve as a Class III director of the Board, effective April 30, 2026
Robert Dozier, Jr., Jason Enoch, Alan Levine and Michael Nieri, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director
Mr. Nieri’s employment terminated
John G. (Jack) Micenko, Jr., Keith Feldman, Michael Nieri, Clive R. G. (Tom) O’Grady, Robert Penny, Jeremy Pyle and Shelton Twine, each of whom was an officer of the Company immediately prior to the Effective Time, ceased to be an officer
John G. (Jack) Micenko, Jr., Keith Feldman, Michael Nieri, Clive R. G. (Tom) O’Grady, Robert Penny, Jeremy Pyle and Shelton Twine, each of whom was an officer of the Company immediately prior to the Effective Time, ceased to be an officer
John G. (Jack) Micenko, Jr., Keith Feldman, Michael Nieri, Clive R. G. (Tom) O’Grady, Robert Penny, Jeremy Pyle and Shelton Twine, each of whom was an officer of the Company immediately prior to the Effective Time, ceased to be an officer
Robert Dozier, Jr., Jason Enoch, Alan Levine and Michael Nieri, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director
John G. (Jack) Micenko, Jr., Keith Feldman, Michael Nieri, Clive R. G. (Tom) O’Grady, Robert Penny, Jeremy Pyle and Shelton Twine, each of whom was an officer of the Company immediately prior to the Effective Time, ceased to be an officer
Robert Dozier, Jr., Jason Enoch, Alan Levine and Michael Nieri, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director
John G. (Jack) Micenko, Jr., Keith Feldman, Michael Nieri, Clive R. G. (Tom) O’Grady, Robert Penny, Jeremy Pyle and Shelton Twine, each of whom was an officer of the Company immediately prior to the Effective Time, ceased to be an officer
Robert Dozier, Jr., Jason Enoch, Alan Levine and Michael Nieri, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director
John G. (Jack) Micenko, Jr., Keith Feldman, Michael Nieri, Clive R. G. (Tom) O’Grady, Robert Penny, Jeremy Pyle and Shelton Twine, each of whom was an officer of the Company immediately prior to the Effective Time, ceased to be an officer
James Rinn provided notice to PSQ Holdings, Inc. (the “Company”) of his resignation from the position of Chief Financial Officer of the Company, effective April 30, 2026.
effective immediately after the Effective Time, the Company appointed Ying Luo, Ph.D. as Chief Executive Officer and President of the Company and to the Board as a Class I director.
Thomas Eastling and Songjiang Ma resigned from the board of directors of the Company (the "Board") and any respective committee of the Board to which they were members, and Mr. Ma also resigned from his position as President of the Company on such date.
Ruoyu Chen, who resigned from her position as Chief Financial Officer on such date.
Thomas Eastling and Songjiang Ma resigned from the board of directors of the Company (the "Board") and any respective committee of the Board to which they were members
the Company appointed Thomas Eastling as Chief Financial Officer of the Company, to succeed Ruoyu Chen, who resigned from her position as Chief Financial Officer on such date.
On May 4, 2026, the Board of Directors of the Company (the “Board”) appointed Paul Campbell, Viatris’ current Chief Accounting Officer and Corporate Controller, to also serve as interim Chief Financial Officer of the Company, effective May 8, 2026, until a permanent Chief Financial Officer is appointed by the Board.
On May 1, 2026, Theodora (“Doretta”) Mistras informed Viatris Inc. (the “Company”) that she would voluntarily cease to serve as Chief Financial Officer to pursue another professional opportunity.
Dr. Elisabet de los Pinos, the Company’s founder, who has notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date
notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date
the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) appointed Natalie Holles as the Company’s Chief Executive Officer and President and as a Class I director with a term expiring at the Company’s 2028 annual meeting of stockholders, effective as of April 30, 2026
Steven Wood Presley, William Lewis McFarland II, Alan Humes and Stephane Bellemare were appointed as the directors of the Company, effective as of the Effective Time.
each of Dr. Albert Bolles, Rebecca Fisher, Dean Hollis, David J. Lemmon, Diego Reynoso, Leslie Starr and Mahes S. Wickramasinghe resigned as a member of the Company’s board of directors, and any committee thereof, effective as of the Effective Time.
each of Dr. Albert Bolles, Rebecca Fisher, Dean Hollis, David J. Lemmon, Diego Reynoso, Leslie Starr and Mahes S. Wickramasinghe resigned as a member of the Company’s board of directors, and any committee thereof, effective as of the Effective Time.
Steven Wood Presley, William Lewis McFarland II, Alan Humes and Stephane Bellemare were appointed as the directors of the Company, effective as of the Effective Time.
each of Dr. Albert Bolles, Rebecca Fisher, Dean Hollis, David J. Lemmon, Diego Reynoso, Leslie Starr and Mahes S. Wickramasinghe resigned as a member of the Company’s board of directors, and any committee thereof, effective as of the Effective Time.
each of Dr. Albert Bolles, Rebecca Fisher, Dean Hollis, David J. Lemmon, Diego Reynoso, Leslie Starr and Mahes S. Wickramasinghe resigned as a member of the Company’s board of directors, and any committee thereof, effective as of the Effective Time.
each of Dr. Albert Bolles, Rebecca Fisher, Dean Hollis, David J. Lemmon, Diego Reynoso, Leslie Starr and Mahes S. Wickramasinghe resigned as a member of the Company’s board of directors, and any committee thereof, effective as of the Effective Time.
Steven Wood Presley, William Lewis McFarland II, Alan Humes and Stephane Bellemare were appointed as the directors of the Company, effective as of the Effective Time.
each of Dr. Albert Bolles, Rebecca Fisher, Dean Hollis, David J. Lemmon, Diego Reynoso, Leslie Starr and Mahes S. Wickramasinghe resigned as a member of the Company’s board of directors, and any committee thereof, effective as of the Effective Time.
each of Dr. Albert Bolles, Rebecca Fisher, Dean Hollis, David J. Lemmon, Diego Reynoso, Leslie Starr and Mahes S. Wickramasinghe resigned as a member of the Company’s board of directors, and any committee thereof, effective as of the Effective Time.
Steven Wood Presley, William Lewis McFarland II, Alan Humes and Stephane Bellemare were appointed as the directors of the Company, effective as of the Effective Time.
On May 4, 2026, the Company appointed Michael Buckner as the new Chief Legal Officer and, as a result, effective on such date, Mr. DiMarco resigned from his positions as Senior Vice President, Chief Legal Officer and Secretary of the Company.
On May 4, 2026, the Company appointed Michael Buckner as the new Chief Legal Officer
appointed Zachary C. Lauer to serve as the Company’s Senior Vice President, Chief Operations Officer effective immediately.
the Board appointed Brian Burkavage, the Company’s current Senior Vice President, Finance, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Time.
the Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) determined that, effective as of May 1, 2026 (the “Effective Time”), Lori Firmani would cease serving as the Company’s Chief Financial Officer.
On May 4, 2026, Adeia Inc. (the “Company” or “Adeia”) announced that Paul E. Davis, the Company’s chief executive officer, notified the Company and the Board of Directors (the “Board”) on May 4, 2026, of his intention to step down as the Company’s chief executive officer and as a member of the Board to focus on his health and personal pursuits.
On April 28, 2026, the Board of Directors of Madison Square Garden Sports Corp. (the "Company") appointed Paul DiCicco as Executive Vice President, Chief Financial Officer and Treasurer effective May 11, 2026 or such later date as may be agreed (the "Commencement Date").
Ms. Acosta will assume the responsibilities of principal accounting officer from Amrita Ahuja, who has been serving as interim principal accounting officer. Ms. Ahuja will continue in her roles as the Company’s Chief Financial Officer and Chief Operating Officer.
On April 30, 2026, the Board of Directors of Block, Inc. (the “Company”) appointed Andrea Acosta as the Company’s Chief Accounting Officer (principal accounting officer), effective as of May 26, 2026.
Effective as of April 29, 2026, the following individuals were appointed to the board of directors of the Company: Jean-Michel Enriquez Dahlhaus, and Hector Madero Rivero.
Effective as of April 29, 2026, the following individuals were appointed to the board of directors of the Company: Jean-Michel Enriquez Dahlhaus, and Hector Madero Rivero.
Additionally, the Board appointed John E. Stokely, Chair of the Board, as Executive Chair effective on May 4, 2026.
Mr. Arvan will also resign as a member of the Company’s Board of Directors (the “Board”), effective at the Transition Effective Time.
David G. Whalen will serve as lead independent director in the interim and receive a monthly fee of $5,000 for the period he serves in such role
The Board has appointed John B. Watwood as President and Chief Executive Officer, effective as of the Transition Effective Time.
On May 4, 2026, Pool Corporation (the “Company”), a Delaware corporation, and Peter D. Arvan mutually agreed that Mr. Arvan will cease to serve as President and Chief Executive Officer, effective May 4, 2026
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.